Beyond Semaglutide: The Next Wave of Weight Loss Peptides Coming Soon

The GLP-1 revolution is only in its early innings. Behind semaglutide and tirzepatide, a deep pipeline of next-generation weight loss peptides is advancing through clinical trials. Some target new receptor pathways. Others solve the injection problem entirely. Here is a comprehensive look at the drugs that could define the next chapter of obesity treatment.

The Current Landscape

Today's GLP-1 market is dominated by two molecules: semaglutide (Novo Nordisk's Wegovy/Ozempic) and tirzepatide (Eli Lilly's Zepbound/Mounjaro). Together, they generate tens of billions in annual revenue and have fundamentally changed how the medical community approaches obesity.

But pharmaceutical companies are racing to develop next-generation compounds that could be more effective, more convenient, or both. The pipeline is remarkably deep, with several candidates in late-stage clinical trials.

Orforglipron (Eli Lilly)

Mechanism: Oral GLP-1 receptor agonist (non-peptide small molecule)

Orforglipron is perhaps the most commercially significant drug in the pipeline. Unlike oral semaglutide (which is a peptide that requires a special absorption enhancer and fasting protocol), orforglipron is a small molecule — meaning it can be absorbed like a traditional pill without the same dietary restrictions.

In Phase 2 trials, orforglipron produced up to 14.7% weight loss at 36 weeks. Phase 3 results are pending, but if confirmed, this could be the first truly convenient oral GLP-1 option — no fasting requirement, no injection, and potentially lower manufacturing costs.

If orforglipron succeeds, it could dramatically expand the market for GLP-1 therapy. A simple daily pill with no fasting requirement and no needles removes virtually every practical barrier to treatment. It could also drive costs down significantly, as small-molecule drugs are cheaper to manufacture than peptides.

Survodutide (Boehringer Ingelheim)

Mechanism: Dual GLP-1/glucagon receptor agonist

Survodutide takes a different approach from tirzepatide by combining GLP-1 with glucagon receptor activation (instead of GIP). The glucagon component increases energy expenditure and promotes liver fat reduction — making it particularly promising for patients with non-alcoholic fatty liver disease (NAFLD/MASH) alongside obesity.

Phase 2 data showed up to 18.7% weight loss at 46 weeks, with remarkable improvements in liver fat (up to 87% reduction). Phase 3 trials are underway for both obesity and MASH indications.

Amycretin (Novo Nordisk)

Mechanism: Dual GLP-1/amylin receptor agonist

Novo Nordisk's amycretin combines GLP-1 with amylin receptor agonism — a novel approach. Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying. Early Phase 1 data showed up to 13.1% weight loss in just 12 weeks — an unprecedented rate of weight loss for such a short study.

If this trajectory holds in larger, longer trials, amycretin could produce weight loss exceeding even retatrutide. However, the drug is still in early clinical development, so caution is warranted.

CagriSema (Novo Nordisk)

Mechanism: Fixed-dose combination of cagrilintide (amylin analog) + semaglutide

Rather than engineering a single molecule with multiple targets, CagriSema is a combination product that pairs two proven mechanisms. In the REDEFINE Phase 3 trial, CagriSema achieved 22.7% weight loss at 68 weeks — better than either component alone and competitive with tirzepatide.

CagriSema is in late-stage development and could be one of the next obesity medications to reach the market. Its combination approach may also offer a differentiated side effect profile compared to single-molecule multi-agonists.

Pemvidutide (Altimmune)

Mechanism: Dual GLP-1/glucagon receptor agonist

Pemvidutide is another dual GLP-1/glucagon agonist, similar in concept to survodutide but from a smaller biotech company. Phase 2 data showed approximately 15.6% weight loss at 48 weeks, with significant liver fat reduction. It is being developed for both obesity and MASH.

What This Means for Patients

The pipeline is genuinely exciting, but most of these drugs are 2-5 years from potential FDA approval. For patients considering GLP-1 therapy, the message is clear: do not wait for the next generation if current medications can help you today.

Semaglutide and tirzepatide are producing transformative results right now. Providers like Measured offer both compounded and branded options at accessible price points, with the flexibility to transition to newer medications as they become available.